Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pro Medicus Limited ( (AU:PME) ) has issued an announcement.
Pro Medicus Limited has released its annual report for the year ending June 30, 2025, emphasizing its commitment to integrated reporting. The report outlines the company’s adherence to the International Integrated Reporting Framework, aiming for transparency and long-term value creation. It includes comprehensive information on Pro Medicus’ operations, governance, and financial performance. The company has implemented rigorous processes to ensure the integrity of its reporting, including independent audits and stakeholder engagement. This approach is expected to enhance the company’s industry positioning and stakeholder trust.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, providing advanced imaging software solutions. The company is focused on delivering integrated reporting and sustainable value creation through its international operations in Berlin, San Diego, and Melbourne.
Average Trading Volume: 172,667
Technical Sentiment Signal: Buy
Current Market Cap: A$31.67B
For a thorough assessment of PME stock, go to TipRanks’ Stock Analysis page.